Table 3.
Distribution of the examined markers
| N (%) | |
|---|---|
|
ER (n = 938) |
|
| Negative |
245 (26.1) |
| Positive |
693 (73.9) |
|
PgR (n = 940) |
|
| Negative |
301 (32.0) |
| Positive |
639 (68.0) |
|
Ki67 (n = 934) |
|
| Low |
299 (32.0) |
| High |
635 (68.0) |
|
alphaB-crystallin (n = 940) |
|
| Negative |
770 (81.9) |
| Weakly positive |
99 (10.5) |
| Strongly positive |
71 (7.6) |
|
BRCA1 (n = 928) |
|
| Negative |
863 (93.0) |
| Positive |
65 (7.0) |
|
BRCA1
(n = 86) |
|
| WT |
78 (90.7) |
| Mutated |
8 (9.3) |
|
p53 (n = 918) |
|
| Negative |
445 (48.5) |
| Positive |
473 (51.5) |
|
EGFR (n = 928) |
|
| Negative |
777 (83.7) |
| Positive |
151 (16.3) |
|
CK5 (n = 923) |
|
| Negative |
802 (86.9) |
| Positive |
121 (13.1) |
|
CK14 (n = 925) |
|
| Negative |
894 (96.6) |
| Positive |
31 (3.4) |
|
CK17 (n = 909) |
|
| Negative |
884 (97.2) |
| Positive | 25 (2.8) |
WT, wild-type.